At a glance
ClinicalIndex Comparison RecordPhase 1Completed· 12 enrolled
Drug / intervention
PF-05175157 +1 moredrug
Likely dose
PF-05175157 600 mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Phase 1 Randomized, Double-blind, Placebo-controlled, Two-way Crossover Study To Assess The Effect Of Pf-05175157 As A Single Oral Dose On Metabolic And Cardiopulmonary Parameters During Steady State And Graded Exercise In Healthy Subjects
In Brief
A Phase 1 clinical trial evaluating PF-05175157 and Placebo for Healthy. Completed, enrolled 12 participants across 1 site.
Detailed Summary
This study is designed to assess the effect of one single dose of PF-05175157 on metabolic and cardiopulmonary parameters before, during and after treadmill exercise in healthy volunteers.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsHealthy
CountriesUnited States
Collaborators--
Timeline
Phase 1CompletedFinished
20132014201520162017201820192020202120222023202420252026
First PostedMar 2013
Enrollment StartApr 2013
Primary CompletionOct 2013
TodayJul 2026
First PostedMar 28, 2013
Enrollment StartApr 1, 2013
Primary CompletionOct 1, 2013
TodayJul 2, 2026
Enrollment to primary: 6 monthsPosted 13.3 years ago
Interventions
PF-05175157drug
600 mg as powder in capsule, one dose within 5 minutes prior to AM meal
Placebodrug
Placebo powder in capsule, one dose within 5 minutes prior to AM meal